![](/images/graphics-bg.png)
Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
Joint Authors
Parrott, Jessica
Holland, Marium
Source
Case Reports in Obstetrics and Gynecology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-09-17
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
Cytarabine use during pregnancy carries a 5–7% risk of neonatal cytopenia.
We report two cases of fetal myelosuppression following high-dose cytarabine administration for acute myeloid leukemia (AML).
Case 1.
A 36-year-old G9P6 diagnosed with AML at 21 weeks was monitored for fetal anemia weekly and growth monthly.
At 33 weeks (after 2 cycles), BPP was 2/10 and MCA PSV was elevated at 1.51 MoM.
Urgent cesarean section was performed.
The infant had an initial pH of 6.78 and pancytopenia (hematocrit 13.3%, platelets 3 K/UL, and white blood cell count 2.0 K/UL).
Initially transfusion dependent, the neonate had count recovery by 3 weeks.
Case 2.
A 30-year-old G4P3 with AML at 26 weeks was monitored for fetal anemia twice weekly and growth monthly.
At 34 weeks (after cycle 1), she was admitted with neutropenic fever.
The fetal MCA PSV was borderline at 1.48 MoM.
It improved to 1.38 MoM at 35 weeks but the fetal tracing worsened.
At delivery the fetus was found to have a hematocrit of 30%, but with normal platelet and WBC.
The fetus did not require any transfusions.
Conclusion.
Cytarabine use during pregnancy may cause neonatal myelosuppression.
We recommend monitoring for fetal anemia with MCA Dopplers twice weekly.
American Psychological Association (APA)
Parrott, Jessica& Holland, Marium. 2017. Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?. Case Reports in Obstetrics and Gynecology،Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1147392
Modern Language Association (MLA)
Parrott, Jessica& Holland, Marium. Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?. Case Reports in Obstetrics and Gynecology No. 2017 (2017), pp.1-5.
https://search.emarefa.net/detail/BIM-1147392
American Medical Association (AMA)
Parrott, Jessica& Holland, Marium. Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?. Case Reports in Obstetrics and Gynecology. 2017. Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1147392
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147392